Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zibotentan/Dapagliflozin in Chronic Kidney Disease and High Proteinuria
NCT06087835Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2023
- Primary completion
- Feb 2027
- Countries
- 30
01
Overview
A Phase 3 trial of zibotentan in chronic kidney disease (CKD), sponsored by AstraZeneca. Started Nov 2023; status: active, not recruiting.
02
Drugs
zibotentan
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06087835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06087835.